140.92
+2.13(+1.53%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
879
First IPO Date
January 28, 2015
| Name | Title | Pay | Year Born |
| Mr. Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director | 0 | 1960 |
| Mr. Mads Bodenhoff | Senior Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President & Head of Clinical Development for Oncology | 0 | 1974 |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research & Product Development | 0 | 1979 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | 0 | 1969 |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | 0 | 1961 |
| Ms. Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board | 0 | 1961 |
| Mr. Timothy J. Lee | Senior Director of Investor Relations | 0 | N/A |
| Mr. Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board | 0 | 1974 |
| Mr. Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer & Member of the Executive Board | 0 | 1971 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.